Etravirine: all 45 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)CompletedNCT04630002Phase 1Results posted
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedNCT02212379Phase 2Results posted
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedNCT01641367Phase 4Results posted
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenCompletedNCT01504841Phase 1/2Results posted
- Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative VolunteersCompletedNCT01427504Not applicableResults posted
- A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsCompletedNCT01199939Phase 2Results posted
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected ParticipantsCompletedNCT00980538Phase 3Results posted
- Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV InfectionCompletedNCT00959894Phase 2Results posted
- A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected PatientsCompletedNCT00903682Phase 2Results posted
- Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot StudyCompletedNCT00871234Phase 1Results posted
- HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineTerminatedNCT00855413Phase 4Results posted
- A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenCompletedNCT00855335Phase 3Results posted
- TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsCompletedNCT00665847Phase 2Results posted
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
- A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).CompletedNCT00534352Phase 2Results posted
- Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.CompletedNCT00460746Phase 3Results posted
- An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).CompletedNCT00359021Phase 3Results posted
- A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyCompletedNCT00128830Phase 2Results posted
- Safety and Efficacy of Etravirine in Friedreich Ataxia PatientsCompletedNCT04273165Phase 2
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult ParticipantsCompletedNCT04208373Phase 1
- Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected PatientsCompletedNCT02818348Phase 1
- DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedNCT02063360Phase 1
- Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / LumefantrineCompletedNCT01876966Phase 1
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected PatientsCompletedNCT01422330Phase 4
- Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once DailyCompletedNCT01121809Phase 4
- The First Failure StudyTerminatedNCT01118871Phase 4
- TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected PatientsCompletedNCT01090648Phase 1
- A Pilot Study of Kaletra and Intelence Tablets in Naive SubjectsCompletedNCT01045369Phase 4
- Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia SuppressionCompletedNCT01034917Phase 3
- GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/RitonavirCompletedNCT00867152Phase 1
- Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueCompletedNCT00855088Phase 1
- TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.CompletedNCT00828815Phase 1
- Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and EfavirenzCompletedNCT00792584Not applicable
- Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125CompletedNCT00792324Phase 3
- Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
- TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.CompletedNCT00767117Phase 1
- TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.CompletedNCT00740389Phase 1
- TMC 125 Blood Levels StudyCompletedNCT00531323Phase 1
- Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant VirusesCompletedNCT00460382Phase 2
- TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected PatientsCompletedNCT00412646Phase 2
- TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.CompletedNCT00255099Phase 3
- TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.CompletedNCT00254046Phase 3
- TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI UseCompletedNCT00225303Phase 2
- TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 TrialCompletedNCT00111280Phase 2
- TMC125-C223: TMC125 in HIV-1 Infected SubjectsCompletedNCT00081978Phase 2